Results 81 to 90 of about 43,976 (245)

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection

British Journal of Clinical Pharmacology, EarlyView.
Background and Aim The rise of drug‐resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ‐587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ‐587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and ...
Albin A. M. Leding, Paul Bruinenberg, Almari Conradie, Jerry Nedelman, Antonio Lombardi, Dean Hickman, Ulrika S. H. Simonsson   +6 more
wiley   +1 more source

Comparision of doxorubicin-induced cardiotoxicity in the ICR mice of different sources

Laboratory Animal Research, 2017
Doxorubicin is a widely used chemotherapeutic agents and is now part of standard therapeutic regimens for a variety of cancers (eg, hematopoietic malignancies and advanced solid tumors of the breast, ovary, thyroid, and bone).
Sou Hyun Kim, Keuk-Jun Kim, Joung-Hee Kim, Jae-Hwan Kwak, HyunKeun Song, Joon Young Cho, Dae Youn Hwang, Kil Soo Kim, Young-Suk Jung   +8 more
doaj   +1 more source

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol ...
Andriy A. Gorbenko, Titiaan E. Post, Pamela K. Strugala, Erica S. Klaassen, Linda E. Klumpers, Saco J. de Visser, Cristina Sempio, Jost Klawitter, Jules A. A. C. Heuberger, Geert J. Groeneveld   +9 more
wiley   +1 more source

Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment

Cancer Management and Research, 2022
Matthew Anaka, Omar Abdel-Rahman Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, CanadaCorrespondence: Omar Abdel-RahmanDepartment of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue ...
Anaka M, Abdel-Rahman O
doaj  

Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

British Journal of Clinical Pharmacology, EarlyView.
Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon, Hinke Huisman‐Siebinga, Shelby Barnett, Paul Wetherell, Pamela Kearns, Brenda Gibson, Nicholas Heaney, Owen Smith, André Baruchel, Arnaud Petit, Andrew Moore, Kayode Ogungbenro, Alwin D. R. Huitema, Gareth J. Veal   +13 more
wiley   +1 more source

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

BMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai, Rui Zhang, Haiyin Yang, Jiyue Xing, Tianyuan Hu, Mengxi Zhu, Rui Li, Xiaoli Chen, Beibei Zhao, Yang Lan, Stefan Barth, Yuanyu Huang, Li Zhang, Mengjie Zhang, Huining He   +14 more
wiley   +1 more source

Deubiquitinase MYSM1 promotes doxorubicin-induced cardiotoxicity by mediating TRIM21-ferroptosis axis in cardiomyocytes

Cell Communication and Signaling
Anthracycline antitumor drug doxorubicin (DOX) induces severe cardiotoxicity. Deubiquitinating enzymes (DUBs) are crucial for protein stability and function and play a significant role in cardiac pathophysiology.
Xiaowen Shi, Jianjiang Xu, Xin Zhong, Yuanyuan Qian, Liming Lin, Zimin Fang, Bozhi Ye, Yiting Lyu, Ran Zhang, Zhanxiong Zheng, Jibo Han   +10 more
doaj   +1 more source

Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
External comparator cohort (ECC) studies with real‐world data (RWD) may provide more reliable estimates of treatment differences compared to single‐arm trials (SAT), yet they face limitations such as selection bias and data heterogeneity. This study assessed the perceived strength of evidence of ECC studies compared to SAT and randomized controlled ...
Francesco Pignatti, Tarec Christoffer El‐Galaly, Martin Kaiser, Kimmo Porkka, Robin Doeswijk, Peter Mol, Donna R. Rivera, Catherine C. Lerro, Ulrich‐Peter Rohr, Patrice Verpillat, Antonios Valachis, Dario Trapani, Massimo Di Maio, Nicola Latino, Raul Cordoba, Nathan Cherny, Miriam Koopman, Diogo Martins‐Branco, George Pentheroudakis, Douwe Postmus   +19 more
wiley   +1 more source

Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults

Clinical Pharmacology &Therapeutics, EarlyView.
Cannabidiol (CBD) is one of the most abundant bioactive cannabinoids. Research has demonstrated CBD’s ability to inhibit metabolic enzymes like cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT), potentially leading to drug interactions. However, clinical knowledge gaps remain, particularly with regard to drugs that are more commonly taken by ...
Pablo Salcedo, Donna A. Volpe, Anik Chaturbedi, Aanchal Shah, Ashok Krishna, Paula L Hyland, Giri Vegesna, Cheng‐Hui Hsiao, Ryan De Palma, Melanie Fein, Rodney Rouse, Jeffry Florian   +11 more
wiley   +1 more source